IDEXX LABORATORIES INC /DE Share-based Payment Arrangement, Accelerated Cost
IDEXX LABORATORIES INC /DE (IDXX) reported Share-based Payment Arrangement, Accelerated Cost of $8.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2022-02-16
- IDEXX LABORATORIES INC /DE share-based payment arrangement, accelerated cost for fiscal 2021 was $8.00M, a 42.86% increase from fiscal 2020.
- IDEXX LABORATORIES INC /DE share-based payment arrangement, accelerated cost for fiscal 2020 was $5.60M, a 47.37% increase from fiscal 2019.
- IDEXX LABORATORIES INC /DE share-based payment arrangement, accelerated cost for fiscal 2019 was $3.80M.
| Period end | Share-based Payment Arrangement, Accelerated Cost 12 month |
|---|---|
| 2021-12-31 | $8.00M 10-K · filed 2022-02-16 |
| 2020-12-31 | $5.60M 10-K · filed 2021-02-12 |
| 2019-12-31 | $3.80M 10-K · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |